The patient comes first

Article

Ever wondered what it must be like for today's refractive surgeon, having to perform a job to the best of their ability whilst sometimes facing criticism for being "too commercial"? The refractive surgery industry has suffered its fair share of setbacks over recent years and certainly, some clinics have deservedly earned this criticism for not performing the job adequately.

If you treat your patient well and give them the correct support, both before and after surgery, your practice will inevitably gain a good reputation. Suddenly you will find prospective patients arriving at your surgery because their friend or their relative recommended you to them. Not only does this instil patient trust but it will also go towards securing the longevity of your practice. Isn't this how every business wants to operate?

This month I spoke with two inspirational Italian, refractive surgeons who are truly passionate about their trade. Please go to page 19 to find out what Roberto Pinelli and Paolo Fazio had to say about the issues relating to their industry today and how they are making progress towards improving the situation in their wonderful home country of Italy.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.